View Clinical Trial (Medical Research Study)
Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence
| City: |
|
Williamsville |
| State: |
|
New York |
| Zip Code: |
|
14221 |
| Conditions: |
|
Colorectal Cancer - Adenomatous Colorectal Polyps - Precancerous Condition |
| Purpose: |
|
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Selenium may be effective in preventing the recurrence
of adenomatous colorectal polyps.
PURPOSE: This randomized phase III trial is studying selenium to see how well it works in
preventing the recurrence of polyps in patients with adenomatous colorectal polyps.
|
| Study Summary: |
|
OBJECTIVES:
Primary
- Compare the effects of selenium vs placebo on the recurrence of adenomatous colorectal
polyps, in terms of histologic type, degree of dysplasia, number, size, and location,
in patients with adenomatous colorectal polyps.
- Compare the type, incidence, and outcome of side effects in patients treated with these
regimens.
- Determine patient adherence to long-term treatment with these regimens.
Secondary
- Determine the effects of regimen modification by baseline blood selenium level,
low-dose aspirin, selenoprotein genetic marker polymorphisms (e.g., GPx-1, GPx-2, and
SEP15)
- Determine the effects of low-dose aspirin (81 mg/day) modification by ornithine
decarboxylase promoter genotype, and toxicity by slow-metabolizer genotypes of the
cytochrome p450 2C9 and UT1A6 loci in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
are stratified according to use of low-dose (≤ 81 mg/day) aspirin (yes vs no). Patients are
randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral selenium once daily.
- Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for
up to 5 years* in the absence of disease progression or unacceptable toxicity.
Patients undergo follow-up colonoscopy approximately 5 years* after baseline colonoscopy.
NOTE: Some patients will continue participation for up to 7 and a half years
PROJECTED ACCRUAL: A total of 1,600 patients with an adenoma will be randomized to this
study, followed by a second group of randomization of 200 patients with at least one
advanced adenoma (at baseline) for a substudy. Total planned randomizations = 1,800
participants.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Histologically confirmed colorectal adenomatous polyps
- Meets the following criteria by colonoscopy (performed within the past 6 months):
- Cecum was totally visualized or reached
- At least 90% visualization of colon surface area
- Removed at least 1 adenomatous polyp of at least 3 mm in size during procedure
(For the Advanced Adenoma Sub-study: Removal of at least 1 advanced colorectal
adenomatous polyp during procedure. An adenoma is considered advanced if it is
10 mm or greater in size, and/or has villous histology and/or shows high grade
dysplasia)
- Removed no more than 10 adenomatous polyps of any size by endoscopy
- All other neoplastic and non-neoplastic colon polyps must have been completely
removed (except for diminutive [less than 3 mm] sessile rectal polyps)
- For the sub-study, at least 1 advanced adenomatous polyp defined as 10 mm or
greater in size and/or has villous histology and/or shows high grade dysplasia
- No prior diagnosis of any of the following:
- Colorectal cancer
- Familial adenomatous polyposis
- Ulcerative colitis
- Crohn's disease
- Hereditary non-polyposis colon cancer (HNPCC), defined as:
- Histologically confirmed colorectal cancer in at least 3 relatives, 1 of
whom is a first-degree relative of the other 2
- Disease occurrence in at least 2 consecutive generations
- Colorectal cancer diagnosis in at least 1 family member who is less than 50
years of age
- Patients with a family history of colorectal cancer but who are not
diagnosed with HNPCC are allowed
- No more than 1 prior segmental colon resection
PATIENT CHARACTERISTICS:
Age
- 40 to 80
Performance status
- SWOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Hemoglobin > 11 g/dL
- WBC 3,000 - 11,000/mm^3
Hepatic
- AST and ALT < 2 times upper limit of normal
- Bilirubin < 2.0 mg/dL
Renal
- Creatinine < 1.9 mg/dL
Cardiovascular
- No unstable* cardiac disease despite medication (e.g., diuretics or digitalis)
- No uncontrolled hypertension (i.e., systolic blood pressure ≥ 170 mm Hg and/or
diastolic blood pressure ≥ 110 mm Hg) despite medication NOTE: *Unstable defined as
unable to walk across the room without chest pain or shortness of breath
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception for at least 2 months before and
during study treatment
- Resident of a clinical center metropolitan area or obtaining regular health care in a
clinical metropolitan area for at least 6 months out of the year
- Must be able to swallow pills
- No unexpected weight loss of 10% or more within the past 6 months
- No prior rheumatoid arthritis
- No poorly controlled diabetes mellitus despite medication, defined as:
- Blood sugar level ≥ 200 mg/dL on more than half of the readings taken within the
past month
- No invasive malignancy within the past 5 years that required medical excision,
radiotherapy, or chemotherapy except basal cell or squamous cell carcinoma
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent drugs that regulate the immune system
Chemotherapy
- No concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No concurrent radiotherapy
Surgery
- See Disease Characteristics
Other
- Prior enrollment in another adenoma prevention study allowed
- Concurrent routine aspirin (≤ 81 mg/day) allowed
- No regular use of non-steroidal anti-inflammatory drugs (NSAIDs)
- No concurrent enrollment in another research study using pharmacological cancer
drugs, a cyclo-oxygenase-2 inhibitor, or selenium
- No other concurrent selenium unless dosage is ≤ 50 µg/day
|
| NCT ID: |
|
NCT00078897 |
| Primary Contact: |
|
Principal Investigator
M. Peter Lance, MD
University of Arizona
Liane Fales, RN
Phone: 602-264-4461
Email: lfales@email.arizona.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Williamsville, New York 14221
United States
Pat Graham, RN
Phone: 706-332-2203
Email: pgraham@ecwny.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|